Exempt Drugs from Prescription Drug Affordability Board Reviews
| Type | Bill |
|---|---|
| Session | 2026 Regular Session |
| Subjects |
Concerning exempting certain drugs from the scope of affordability reviews conducted by the Colorado prescription drug affordability review board.
Bill Summary:
The bill states that the Colorado prescription drug affordability review board has no authority to perform an affordability review of, or to establish an upper payment limit for, a prescription drug that is:
- Designated as a drug for a rare disease or condition by the food and drug administration (FDA) of the federal department of health and human services; or
- A licensed biological product that is derived from human whole blood or plasma as indicated on product labeling approved by the FDA.(Note: This summary applies to this bill as introduced.)
Prime Sponsors
Senator
Lisa Frizell
Senator
Janice Marchman
Representative
Lindsay Gilchrist
Representative
Dusty Johnson
Committees
Senate
Health & Human Services
If you require reasonable accessibility accommodation to access this content, please email accessibility@coleg.gov.
Related Documents & Information
| Date | Version | Documents |
|---|---|---|
| 03/16/2026 | Introduced |
| Activity | Vote | Documents |
|---|---|---|
| Refer Senate Bill 26-140 to the Committee of the Whole. | The motion passed on a vote of 5-2. | Vote summary |
| Date | Location | Action |
|---|---|---|
| 04/02/2026 | Senate | Senate Committee on Health & Human Services Refer Unamended to Senate Committee of the Whole |
| 03/16/2026 | Senate | Introduced In Senate - Assigned to Health & Human Services |
Prime Sponsor
Sponsor
Co-Sponsor